New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials

Estimated Prevalence of Heterozygous Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome

(2017) Hirotoshi Ohmura et al.   International Heart Journal

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

(2017) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction

(2016) Sofie Aagaard Rerup et al.   AMERICAN HEART JOURNAL

Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary AngiographyHighlights

(2016) Jian-Jun Li et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins

(2016) Loukianos S. Rallidis et al.   ATHEROSCLEROSIS

PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia

(2016) Rodrigo Alonso et al.   ATHEROSCLEROSIS

Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary SyndromesClinical Perspective

(2016) David Nanchen et al.   CIRCULATION

Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins　– ODYSSEY JAPAN Randomized Controlled Trial –

(2016) Tamio Teramoto et al.   CIRCULATION JOURNAL

Challenges in the health economics of familial hypercholesterolemia

(2016) Richard Norman et al.   CURRENT OPINION IN LIPIDOLOGY

Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217

(2016) Marianne Benn et al.   EUROPEAN HEART JOURNAL

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

(2016) Ulf Landmesser et al.   EUROPEAN HEART JOURNAL

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial

(2016) Patrick M. Moriarty et al.   EUROPEAN HEART JOURNAL

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

(2016) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization

(2016) Barak Zafrir et al.   Journal of Clinical Lipidology

Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation

(2016) Martin Bødtker Mortensen et al.   Journal of Clinical Lipidology

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

(2016) Donald M. Lloyd-Jones et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

(2016) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

(2015) Guy De Backer et al.   ATHEROSCLEROSIS

Cardiac computed tomography imaging in familial hypercholesterolaemia

(2015) Eric J.G. Sijbrands et al.   CURRENT OPINION IN LIPIDOLOGY

Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death

(2015) Henriette Walaas Krogh et al.   EUROPEAN HEART JOURNAL

Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes

(2015) David Nanchen et al.   EUROPEAN HEART JOURNAL

Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction

(2015) David S. Wald et al.   European Journal of Internal Medicine

Prevalence and treatment of familial hypercholesterolaemia in Australian communities

(2015) Gerald F. Watts et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia

(2015) Dick C. Chan et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit

(2015) Jing Pang et al.   Journal of Clinical Lipidology

Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?

(2015) Robert P. Giugliano et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Lipoprotein(a) Levels in Familial Hypercholesterolemia

(2014) Rodrigo Alonso et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

(2014) Gerald F Watts et al.   European Journal of Preventive Cardiology

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

(2013) Gerald F. Watts et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Familial-combined hyperlipidaemia in very young myocardial infarction survivors (

(2009) F. Wiesbauer et al.   EUROPEAN HEART JOURNAL

Long-term prognostic factors of young patients (≤ 35 years) having acute myocardial infarction: the detrimental role of continuation of smoking

(2008) Loukianos S. Rallidis et al.   EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION

Detection of Familial Hypercholesterolaemia: A Major Treatment Gap in Preventative Cardiology

(2007) Timothy R. Bates et al.   Heart Lung and Circulation